Form 4: Larimar Therapeutics Director Acquires 19,000 Stock Options
SEC Form 4 Filing
Director Joseph Truitt acquired 19,000 stock options in Larimar Therapeutics, Inc. on May 29, 2024.
Summary
- On May 29, 2024, Joseph Truitt, a director of Larimar Therapeutics, Inc., acquired 19,000 stock options.
- The options have an exercise price of $7.07.
- The options vest on the earlier of May 29, 2025, or the date of the company's next annual meeting of stockholders, contingent upon continued service on the Board of Directors.
- The options expire on May 29, 2034.
Sentiment
Score: 5
Explanation: This is a neutral event, simply a disclosure of stock option acquisition by a director. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This is a standard Form 4 filing, indicating a change in beneficial ownership by a company insider. Such filings are common and provide transparency into the trading activities of company directors and officers.
Stakeholder Impact
- The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 05/29/2024 | Date of earliest transaction: Director acquired 19,000 stock options. |
| 05/29/2025 | Options vest on the earlier of this date or the date of the Company's next annual meeting of stockholders. |
| 05/29/2034 | Expiration date of the stock options. |
| 05/31/2024 | Date of signature of the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.